To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Australia (ECOS AUS)
Easypod Connect: An Australian Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment
Sponsor: Merck KGaA, Darmstadt, Germany
A observational or N/A phase clinical study on Growth Disorders, this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 10 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Completed NA
-
Feb 2017 — Jan 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- Merck Serono Australia Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .